Mangalam Drugs And Organics Limited (MANGALAM) fundamentals
Mangalam Drugs And Organics Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as MANGALAM (ISIN INE584F01014). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Mangalam Drugs And Organics Limited does
Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemical products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed for research and development) is Bictegravir Na (IH).
Valuation and market data
| Last close | ₹36.46 |
|---|---|
| Market capitalisation | ₹58 crore |
| Enterprise value | ₹81 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.39 |
| Price to sales (TTM) | 0.25 |
| Book value per share | ₹94.22 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon May 23 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹233 crore | ₹-48 crore | ₹-44 crore | 0.00 |
| Mar 2025 | ₹319 crore | ₹5 crore | ₹7 crore | 4.37 |
| Mar 2024 | ₹369 crore | ₹-11 crore | ₹-9 crore | -5.72 |
| Mar 2023 | ₹373 crore | ₹2 crore | ₹1 crore | 0.80 |
| Mar 2022 | ₹451 crore | ₹28 crore | ₹20 crore | 12.42 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 35.6% |
|---|---|
| Foreign institutions (FII) | 0.1% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 64.2% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.